HemaCare Corporation’s latest publication in BioPharm International  sheds light on a topic that has been preoccupying some of the best minds in cell therapy research; the need to ensure a reliable supply of top-notch starting materials for up-and-coming cell and gene therapies.
Unlike traditional medical treatments, the raw materials for these therapies cannot simply be manufactured. Instead, the supply of starting materials relies on a steady influx of voluntary donors willing to take the time to undertake a fairly complex screening process and donate peripheral blood or bone marrow for altruistic reasons. Nor is a reliable donor pool the only criteria necessary to supplying materials for a successful cellular therapeutic. Starting material quality and consistency ultimately determine the reliable efficacy of the final product.